All-trans retinoic acid inhibits growth associated with downregulation of cyclin D1 and can cause low level apoptosis in estrogen receptor positive breast cancer cell lines. The cyclin D1 gene is ampli®ed and/or the protein overexpressed in about one-third of breast cancers. Constitutive expression of cyclin D1 in estrogen receptor positive MCF-7 and ZR-75 breast cancer cells (MCF-7(cycD1) and ZR-75(cycD1)) Increased the fraction of cells in S phase and reduced the G1 accumulation following retinoic acid treatment compared with control cells. However, culture of MCF-7(cycD1) with 1 mM alltrans retinoic acid resulted in about threefold greater growth inhibition compared with vector-transfected cells. Hoechst staining of DNA and in situ DNA end-labeling analysis indicated that MCF-7(cycD1) and ZR-75(cycD1) cultures contained 4 ± 6-fold more retinoic acid-induced apoptotic nuclei as vector-transfected cells. Retinoic acid treatment of vector-transfected clones resulted in Bax protein activation as assessed by exposure of the NH 2 -terminus of Bax but the proportion of cells containing activated Bax was increased in cyclin D-expressing cells treated with retinoic acid. The latter cells also displayed both immunocytochemical and biochemical evidence of translocation of cytochrome c into the cytosol following RA-treatment. Retinoic acid markedly decreased the Bcl-2 levels in MCF-7 and ZR-75 cells. Accordingly, coexpression of Bcl-2 and cyclin D1 rendered the cells resistant to retinoic acid-induced apoptosis. We conclude that constitutive expression of cyclin D1 sensitizes ER-positive breast cancer cells to a retinoic acid-induced mitochondrial death pathway involving Bax activation, cytochrome c release and caspase-9 cleavage. Oncogene (2001) 20, 3506 ± 3518.
Introduction
About 60% of diagnosed breast cancer is estrogen receptor (ER) positive and about half of these neoplasms require estrogen (E2) for growth and tumorigenesis (Lippman, 1985) . The expression of the ER and the retinoic acid receptor (RAR) are highly corelated in breast cancer cells and many ER+ breast cancer cell lines are growth inhibited by retinoic acid (Roman et al., 1992; Vander Burg et al., 1992) . Retinoids such as all-trans retinoic acid (RA) cause growth inhibition, dierentiation or cell death in a variety of cell types (Kastner et al., 1995; Gudas, 1992) , although the mechanism of retinoid-induced cell death is not understood. Similarly, cellular characteristics which confer sensitivity or resistance to RA-induced apoptosis have not been identi®ed. The RARs belong to the nuclear steroid receptor family of ligandinducible transcription factors which activate transcription of a wide variety of genes associated with RA response elements (RAREs) (Meier, 1997; Glass et al., 1997) . The three dierent subclasses of RARs a, b and g form stable heterodimers with the 9-cis retinoic acid receptors (RXRs). Upon interaction with ligand, the receptor complex recruits coactivator proteins such as the p160 family to its C-terminal transactivating function (AF-2) domain as well as a p300 family member. This complex contains histone acetyl transferase activity which is thought to modify chromatin such that recruitment and/or stimulation of the basal transcriptional machinery is facilitated (Chen et al., 1997; Korzus et al., 1998; Kurokawa et al., 1998) .
In addition to ER expression, between one-third and one-half of mammary carcinomas display overexpression of the cyclin D1 protein. Numerous studies have shown that at least 20% of human breast cancers contain DNA ampli®cations at chromosomal region 11q13 which encompasses the cyclin D1 locus (Lammie et al., 1991; Spencer et al., 1997) . Many more ER+ breast tumors exhibit overexpression of cyclin D1 without ampli®cation. Mouse mammary tumor virusdriven cyclin D1 results in mammary tumors with long latency, thus this cyclin is proposed to be an oncogene in mammary epithelium (Schmidt, 1996) .
We have shown that RA-induced growth inhibition in human ER-positive breast cancer cells is associated with downregulation of cyclin D1 and cdk2 protein levels and kinase activity (Teixeira and Pratt, 1997) . In addition to growth inhibition, retinoic acid can also induce apoptosis in breast cancer and other cell types (Manna and Aggarwal, 2000; Zhang et al., 2000; Nagy et al., 1998; Mangiarotti et al., 1998; Elstner et al., 1998) although the mechanism by which this occurs is uncharacterized.
Apoptosis is a programmed process that results in cell death in response to a wide variety of cellular stresses and insults. The detailed mechanisms and pathways employed by the cell to execute the apoptotic program have undergone intensive study. The proteins that regulate apoptosis are widely described and include Bcl-2 and related molecules. Bcl-2, Bcl-x L , Mcl-1, Bcl-W and A1 suppress cell death while Bax, BAK and BOK promote apoptosis (reviewed in Chao and Korsmeyer, 1998; Gross et al., 1999) . Members of the Bcl-2 family have up to four conserved domains designated BH1, 2, 3 and 4 (reviewed in Reed, 1998; Adams and Cory, 1998; Kelekar and Thompson, 1998) . Proapoptotic molecules such as Bax and Bak contain BH1, 2 and 3. Bid and Bad contain only the BH3 domain and serve as integrators of apoptotic signals which result in the cleavage and dephosphorylation respectively of these two proteins (Li et al., 1998) . The BH1 and BH2 domains of the Bcl-2 and Bcl-x L proteins mediate dimerization with Bax and the BH3 domain is required for Bax interaction with these molecules. Hetero-and homodimerization of Bcl-2 family proteins may determine the propensity of a cell to undergo apoptosis in response to various death signals (Salo et al., 1994; Sedlak et al., 1995) . A key function described for the Bcl-2 family of molecules is insertion into the mitochondrial membrane and control of cytochrome c release into the cytoplasm following a cellular stress. Cytoplasmic cytochrome c then forms part of an active`apoptosome' complex which activates downstream proteolytic events leading to cell death (Li et al., 1997) . The hydrophobic C-terminus of the Bax molecule mediates mitochondrial membrane insertion, although, studies of healthy, unstressed cells indicate that Bax is found primarily in the cytoplasm or loosely associated with membranes. Induction of Bax expression as well as physiological death signals results in its translocation to the mitochondrial membrane where it exists as a homodimer or oligomer. Translocation requires a conformational change somehow conveyed by the death signal that results in exposure of the normally buried NH 2 -terminus. Bak and Bid also undergo a conformational change resulting in NH 2 -terminal availability associated with integration into mitochondrial membranes (Gross et al., 1999 and references therein) .
Central to the execution of apoptosis is a family of cysteine proteases called caspases whose sequential proenzymatic activation is integral to both the biochemical and morphological changes associated with apoptosis. Caspases are divided into subgroups based on sequence homology and substrate speci®city. Apical or initiator caspases include caspases-8 and -9 while caspases-2, -3, -6, -7 and -10 are downstream eector caspases involved in apoptosis (Slee et al., 1999 and references therein) . Two main pathways of apoptotic signaling have been described which dier in the mechanism of activation of the caspase cascade as well as the initial caspase activation. Receptormediated apoptosis is induced either through liganded CD95 (Fas/APO-1) or tumor necrosis factor receptor resulting in the recruitment of adapter molecules such as FADD/MORT1 to which procaspase-8 can bind through its N-terminal death eector domain (DED). Apoptosis executed in this manner does not necessarily involve mitochondrial release of cytochrome c (Ashkenazi and Dixit, 1999) . A second pathway is initiated by a wide variety of cellular stresses including chemical and radiation-induced DNA damage which activate mitochondrial release of cytochrome c. Caspase-9 associates with the apoptotic protease activating factor-1 (Apaf-1) and cytosolic cytochrome c resulting in aggregation and self-activation. Caspase-9 is thus the apical caspase in this apoptotic pathway which subsequently activates the eector caspases (Li et al., 1997) .
In the present study we show that RA induces the mitochondrial pathway of apoptosis in breast cancer cells. Since our laboratory and others (Teixeira and Pratt, 1997; Zhou et al., 1997; Bardon and Razanamahefa, 1998) have demonstrated that RA downregulates cyclin D1 in breast cancer cell lines, we wished to determine the ability of constitutively expressed cyclin D1 to abrogate RA-induced G1 arrest in MCF-7 and ZR-75 ER-positive breast cancer cell lines. Surprisingly, rather than preventing growth inhibition, cyclin D1-expressing clones displayed increased sensitivity to RA-induced apoptosis. Thus, cyclin D1 may predispose breast cancers to apoptotic elimination following RA-treatment.
Results
Cyclin D1 expression reduces G1 accumulation and increases S phase cells in RA-treated breast cancer cells Apart from a strong antiproliferative action, a number of studies have recently shown that all-trans RA can induce apoptosis in breast cancer cells either alone or in combination with other nuclear receptor ligands (Mangiarotti et al., 1998; Elstner et al., 1998) . We previously showed that RA-treated MCF-7 cells display a rapid decrease in cyclin D1 mRNA and protein levels associated with a G1 accumulation (Teixeira and Pratt, 1997) . Initially we wished to determine whether constitutive cyclin D1 expression was sucient to overcome the RA-induced G1 block. We therefore transfected MCF-7 and ZR-75 ER-positive breast cancer cells with a cyclin D1 expression plasmid and stable clones were isolated which constitutively overexpress cyclin D1 under the control of the CMV promoter (MCF-7(cycD1), (Figure 1a ) and ZR-75 (cycD1) (Figure 1b) . Expression in the ZR-75 clones was lower than that in MCF-7 stable clones, however these cells constitutively express about twice the level of cyclin D1 as vector-transfected cells. Stable MCF-7(cycD1) clones were then treated with 1 mM RA for up to 72 h and viable cell counts performed. The results in Figure 1c show that rather than diminishing the eects of RA on viable cell numbers, MCF-7(cycD1) growth inhibition was increased by about threefold compared with control vector-transfected cells. Reductions in cell numbers can be the result of decreases in the rate of cell division or increases in the rate of cell death. We ®rst examined the eects of cyclin D1 on cell cycle in RA-treated breast cancer cells. Flow cytometry indicated that a larger percentage of control MCF-7 cells were in G1 phase 24 h after RA treatment compared to the three cyclin D1 clones tested (Figure 1d ). In contrast, nearly double the percentage of the cyclin D1 clones were in S phase at the same time point compared to control cells. After 48 h of RA-treatment, dierential S phase percentages were still evident. At this time point, these numbers represent decreases in S phase fractions compared to untreated cells of 15% and average of only 3% in the control and MCF-7(cycD1) clones respectively. Thus cyclin D1 promoted S phase entry despite RAtreatment. To determine whether cyclin D1 expression had similar eects in ZR-75 cells ectopically expressing cyclin D1, S phase cells were evaluated by assaying BrdU incorporation in the pooled clones of untreated and RA-treated vector-transfected and MCF-7(cycD1) and ZR-75(cycD1) cells. Figure 2 shows that even in the absence of RA, cyclin D1 expression had a pronounced eect on the cell cycle in ZR-75 cells in that 68% of vector-transfected cells were BrdU positive whereas 84% of ZR-75(cycD1) nuclei were positive. Following a 96 h exposure to RA, BrdU-labeled nuclei were reduced to 15% of the total cell number in vectortransfected ZR-75 cells while addition of RA to ZR-75 (cycD1) cells resulted in a markedly smaller decrease in labeled nuclei to only 29% of viable cells. Similar results were found in MCF-7 cells. Thus, these data show that RA causes a profound reduction in viable cell numbers compared with RA-treated control cells without a concomitant decrease in S phase cells in both MCF-7 and ZR-75 cells constitutively expressing cyclin D1. To con®rm that cyclin D1 expressing cells maintained constitutive expression of cyclin D1 after RA treatment, extracts from vector-transfected cells and one each of the MCF-7(cycD1) and ZR-75(cycD1) stable clones were subjected to immunoblot analysis for cyclin D1 expression following culture in the presence cells were transfected with an expression plasmid encoding cyclin D1 and stable clones were isolated in the presence of G418 as described in Materials and methods. Ten mg of protein extracts were immunoblotted from a 10% SDS gel using an anti-cyclin D1 antibody. and were used throughout the study. Immunoreactivity with an anti-actin antibody was used as an internal control for loading. (c) Three pooled vector-transfected (MCF-7) and individual MCF-7(cycD1) clones were cultured in the presence or absence of 1 mM RA for the indicated times. Viable cells were enumerated using Trypan blue exclusion from triplicate cultures and the results expressed as a percentage of the cell number in untreated cultures. (d) Flow cytometric analysis performed as described in Materials and methods of vector-transfected MCF-7 cells and MCF-7(cycD1) stable clones at 24 and 48 h of culture in the presence of 1 mM RA of vehicle or 1 mM RA for 96 h. The result in Figure  2b ,c show that although the level of expression of cyclin D1 in both RA-treated MCF-7(cycD1) and ZR-75(cycD1) clones was reduced by RA treatment, they still remained as high or higher as those in untreated vector-transfected cells. The reduction may be attributed to decreased levels of endogenous cyclin D1 gene expression in the presence of RA (Teixeira and Pratt, 1997) as well as the recently described increased cyclin D1 proteolysis induced by RA (Spinella et al., 1999) . Note that the MCF-7(cycD1) clone used herein had been subjected to several culture passages which may have resulted in selection for reduced levels of cyclin D1 expression.
Breast cancer cells are sensitized to RA-induced apoptosis by cyclin D1 expression
The results above show that cyclin D1 expression decreases G1 accumulation following RA treatment. However, inspection of cultures of both MCF-7 and ZR-75 clones expressing cyclin D1 revealed many morē oating cells were present beginning 72 h post RA compared with RA-treated vector transfected cell cultures, suggesting that the greater reduction in cell numbers in these cultures might be the result of increased apoptosis. We therefore quanti®ed apoptotic cells in control, MCF-7(cycD1) and cultures. Figure 3 shows representative ®elds from control and cyclin D1 expressing clones untreated or treated with RA for 96 h and then stained with Hoechst. Apoptotic nuclei (brightly-stained condensed, and fragmented nuclei) were evaluated from a total of 1000 cells from each coverslip. The results of this enumeration in Figure 4a , indicate that cultures of vector transfected MCF-7 and ZR-75 cells treated with RA contained few apoptotic nuclei (0.5 and 1% respectively). Cyclin D1 expression resulted in a fourfold increase in apoptotic nuclei in MCF-7 cells and a 3.2-fold increase in ZR-75 cells over vector-transfected The presence of 3' free DNA ends consistent with apoptotic cells was assayed to con®rm the results of the Hoechst staining. Apoptotic cells were detected by in situ end-labeling with terminal transferase in vectortransfected and MCF-7(cycD1) cells. The results in Figure 4b demonstrate that very few apoptotic nuclei were detected by terminal transferase labeling in untreated MCF-7(cycD1) cells (i), while numerous labeled nuclei were present in RA-treated MCF-7(cycD1) cells (ii).
Bax NH 2 -terminus is exposed following RA treatment A growing body of evidence has shown that latent Bax protein can be activated by cellular stresses which result in exposure of the NH 2 -terminal residues normally buried in the molecule and its translocation to mitochondrial membranes (Gross et al., 1999) . We therefore employed monoclonal antibody 6A7 (Hsu and Youle, 1997) which speci®cally recognizes the Bax translocation and insertion in mitochondrial membranes is thought to be a key event in the regulation of release of cytochrome c from this organelle (Gross et al., 1999) . RA-treated cultures showed evidence of Bax conformational changes typical of the mitochondrial pathway of cell death. The appearance of cytoplasmic cytochrome c following Figure 5 Immunocytochemistry for Bax NH 2 -terminal epitope. Vector-transfected MCF-7 (a and b) and ZR-75 (c and d) and pooled MCF-7(cycD1) (e and f) and ZR-75(cycD1) cells (g and h) were cultured in vehicle (a, c, e and g) or 1 mM RA (b, d, f and h) for 96 h. Cells were ®xed on coverslips and incubated with monoclonal antibody 6A7. Images were retrieved as described in Materials and methods exposure to RA would also be consistent with death via the mitochondrial pathway. We therefore determined whether RA treatment of MCF-7(cycD1) cells resulted in release of mitochondrial cytochrome c. As expected, immunocytochemistry with a monoclonal antibody against cytochrome c showed punctate cytoplasmic staining, consistent with mitochondrial localization, in untreated cultures of MCF-7(cycD1) (Figure 7a ). In contrast, in many cells in the RAtreated cultures, the immunostaining with anti-cytochrome c became smoother and more diuse, often occluding the nuclei (Figure 7b ). To con®rm these results biochemically, mitochondria-enriched heavy membrane fractions were isolated from these cells after culture in the absence or presence of RA for 96 h and cytochrome c was analysed by immunoblotting ( Figure  7c ). Cytochrome c was readily detected in the mitochondrial fraction from untreated cells. A small amount of cytochrome c was evident in control cytoplasmic extracts of untreated cells which may have been due to small numbers of apoptotic cells in these cultures or low level contamination with mitochondria. In contrast, cytochrome c content in the cytoplasmic fraction increased substantially following RA treatment. A 22 kDa protein cross-reactive with the Figure 6 RA treatment of MCF-7(cycD1) and ZR-75(cycD1) cells results in Bax NH 2 -terminal exposure. MCF-7 and ZR-75 vector or cyclin D1-transfected cells were cultured as described in Figure 5 . One-thousand cells were enumerated on two dierent coverslips for each condition and cells positive for reactivity with monoclonal 6A7 against the NH 2 -terminal epitope of Bax were expressed as a percentage of the total RA induces caspase-9 cleavage in MCF-7 and ZR-75 cells Cytochrome c released from mitochondria in response to death signals binds the caspase activating protein Apaf-1, inducing formation of a large oligomeric protein complex resulting in activation and cleavage of caspase-9. As cleavage of caspase-9 would be consistent with the mitochondrial pathway of apoptosis, we performed immunoblot analysis of cell extracts from three stable clones each of MCF-7(cycD1) and ZR-75(cycD1) cells following a 96 h exposure to RA or vehicle. The results in Figure 8 show that the approximately 44 kDa proform of caspase-9 is present in both MCF-7 and ZR-75 cells although this enzyme appears more abundant in ZR-75 cells. The reported 37 kDa cleavage product indicative of caspase-9 activation was not present in extracts from vehicletreated cells. However, treatment with RA resulted in appearance of the 37 kDa cleavage product of caspase-9 in all cyclin D1-expressing clones. We also assessed RA-induced caspase-9 cleavage in untransfected MCF-7 cells compared with that in a cyclin D1 expressing clone. Figure 8c shows that, consistent with the low level of apoptosis in control cells in response to RA, a small amount of 37 kDa cleavage product is present in these cells after a 96 h exposure to RA, which is considerably less than that observed in the cyclin D1 clone. Thus, together with Bax activation and the release of cytochrome c, these results are consistent with activation of the mitochondrial death pathway by RA in both MCF-7(cycD1) and ZR-75(cycD1) cells.
Bcl-2 prevents cell death in RA-treated MCF-7(cycD1) cells
While the mechanism by which Bcl-2 prevents cell death is still under study, it is clear that decreased levels of Bcl-2 render cells more susceptible to many inducers of cell death. RA in combination with the PPARg ligand, troglitazone, has been reported to decrease Bcl-2 protein levels in breast cancer cells both in vitro and in vivo (Elstner et al., 1998) . RA alone has been found to lower Bcl-2 levels in ER-positive breast cancer cell lines (Rao et al., 2000) . To determine if RA treatment similarly reduces Bcl-2 levels in cultured MCF-7 and ZR-75 cells, we performed immunoblot analysis for Bcl-2 following treatment with RA for 72 h. Bcl-2 levels in both MCF-7 and ZR-75 cells were profoundly decreased (Figure 9a ) and equivalent downregulation was observed in cyclin D1-transfected clones.
Studies of apoptosis in MCF-7 cells treated with a PPARg ligand and all-trans RA have shown that ectopic expression of Bcl-2 can prevent apoptosis in vitro and in vivo induced by this combination of ligands (Elstner et al., 1998) . We therefore sought to determine whether constitutive expression of Bcl-2 could prevent Bax activation and death in RA-treated MCF-7 cells. We therefore cotransfected and selected stable MCF-7 clones with expression plasmids containing Bcl-2 and cyclin D1 (Figure 9b ). Figure 9c compares the results of immunocytochemistry with the Bax 6A7 antibody and Hoechst staining of pooled clones of MCF-7(cycD1) MCF-7(D1/Bcl-2). In agreement with previous experiments, untreated MCF-7(cycD1) cells contained a small Figure 8 RA induces cleavage of caspase-9. Twenty mg of protein extract isolated from 96 h vehicle-treated and RA-treated cultures of MCF-7(cycD1) (a) and ZR-75(cycD1) (b) stable clones and untransfected control MCF-7 cells and an MCF-7(cycD1) clone (c) were separated by 7.5% SDS ± PAGE and subjected to immunoblot analysis with the caspase-9 antibody. The caspase-9 antibody reacts with a 44 kDa procaspase-9 band and the 37 kDa cleavage product percentage (0.5%) of 6A7-positive cells that increased ®vefold after treatment with RA for 96 h. MCF-7(D1/ Bcl-2) cell cultures contained virtually no conformationally altered Bax. While RA treatment resulted in an increased level of 6A7 immunostaining in MCF-7(D1/ Bcl-2) cells, the percentage of positive cells was more than fourfold below that of the RA-treated MCF-7(cycD1) cells. Results of Hoechst staining showed that cultures of untreated MCF-7(cycD1/Bcl-2) cells contained negligible percentages of cells with apoptotic nuclei. Simultaneous expression of Bcl-2 and cyclin D1 reduced the percentage of dying cells by more than ®vefold compared with MCF-7(cycD1) cells. These results indicate that Bcl-2 can prevent both Bax NH 2 -epitope exposure following RA treatment and most of the RA-induced cell death in MCF-7 cells constitutively expressing cyclin D1. Thus RA-mediated Bcl-2 downregulation is probably required for the apoptotic program to proceed in MCF-7(cycD1) cells but is insucient by itself to produce high levels of cell death in vector-transfected cells. Interestingly, the results in Figures 4a, 6 and 9c show a small percentage of untreated vector-transfected MCF-7 and MCF-7(cycD1) cells were positive for conformationally altered Bax, although we were unable to detect signi®cant numbers of apoptotic nuclei in these cultures.
Discussion
Retinoic acid is well known to induce dierentiation, growth inhibition and apoptosis in a cell typedependent manner. This study demonstrates for the ®rst time that all-trans RA by itself can induce small vector and cyclin D1-transfected cells treated with RA or vehicle for 96 h were separated on 10% SDS ± PAGE and immunoblotted with the Bcl-2 antibody. Reactivity with an anti-actin antibody was used as an internal control for gel loading. (c) MCF-7 cells were cotransfected with expression plasmids for cyclin D1 and Bcl-2 and selected in G418 as described in Materials and methods. Stable clones, positive for overexpression of both proteins, were identi®ed by immunoblot analysis with cyclin D1 and Bcl-2 antibodies. (d) MCF-7 vector transfected and MCF-7(cycD1/Bcl-2) cells were plated on coverslips and cultured in the presence or absence of RA for 96 h. Cells were ®xed and immunostained with monoclonal 6A7 or Hoechst to discern apoptotic nuclei as described in Materials and methods. The results are expressed as the percentage of 6A7 positive cells or apoptotic nuclei following enumeration of 1000 cells amounts of apoptosis in breast cancer cells through the mitochondrial death pathway. Breast cancer cell lines that express the ER generally also express the RARa and it is predominately this subpopulation of breast cancer cells that is sensitive to retinoids. While expression of the RARa is important for retinoid sensitivity there is evidence that the RARb, induced upon treatment with all-trans RA (Liu et al., 1996) or transfected into breast cancer cell lines (Seewaldt et al., 1995) , mediates the growth inhibitory and apoptotic eects of RA. Dierentiation and apoptosis are both indued by RA in promyelocytic leukemia (PML) cells and RA-induced cell death has been studied in some detail therein. Both all-trans and 9-cis RA as well as an RARa selective agonist and a pan RAR agonist are all able to induce apoptosis in a caspase-dependent manner in PML (Gianni et al., 2000) . Studies of retinoid-induced cell death in breast cancer cells have primarily focused on RA in combination with other ligands. Ligand for the peroxisome proliferator-activated receptor-g (PPARg) in combination with RA can also produce apoptosis in breast cancer cells associated with a decrease in Bcl-2 levels and this cell death can be inhibited by the overexpression of Bcl-2 (Elstner et al., 1998). The ability of retinoids to countermand cell survival, possibly by lowering Bcl-2 levels, is evident from the observation that cotreatment with RA and a conventional chemotherapeutic agent results in increased cytotoxicity over the drug alone (Wang et al., 2000) . Similarly, Eck et al. (1998) showed that sequential treatment with melatonin and all-trans RA induces apoptosis in both MCF-7 and T47D cells, although the response to either agent alone was simple growth inhibition. These workers also reported a decreased level of Bcl-2 and an increase in Bax following RA and melatonin, although we have not detected changes in Bax expression in either vectortransfected or cyclin D1-transfected MCF-7 and ZR-75 cells treated with RA.
We initially proposed to study the eect of constitutive expression of cyclin D1 for two reasons. Firstly, we have shown previously that RA decreases levels of cyclin D1 in breast cancer cells (Teixeira and Pratt, 1997) and therefore wished to evaluate the ability of constitutive expression of cyclin D1 to confer resistance to RA-induced growth arrest. Surprisingly, while cyclin D1 indeed attenuated the RA-induced G1 arrest of cells, it also sensitized both MCF-7 and ZR-75 cells to RA-induced apoptosis. Secondly, ampli®ca-tion and/or overexpression of cyclin D1 is a frequent early feature of malignant breast epithelium (Schmidt, 1996; Lammie et al., 1991) and RA has been demonstrated to be chemopreventive in breast cancer models (Lippman and Lotan, 2000) .
Why does cyclin D1 expression sensitize the cells to RA-induced apoptosis? A consideration of other death inducers including ionomycin, DNA damage and glucocorticoids points toward a possible role for cyclin:cdk complexes in apoptosis in that synthetic inhibitors of cdks could prevent apoptosis induced by these agents (Shi et al., 1994; Hakem et al., 1999) .
When oncogenes such as c-myc (Evan et al., 1992) , E2F-1 (Qin et al., 1994) , the viral oncoprotein E1A (Rao et al., 1992) and cyclin D1 (Sofer- Levi and Resnitzky, 1996) are expressed in cells in the absence of supporting growth factors or in serum-free medium the cells undergo apoptosis. Apoptosis induced under these conditions is thought to occur in response to the resulting con¯ict in cell signaling.
The overexpression of c-myc and the induction of cell death in the absence of supporting growth factors is the best studied example of the con¯icting proliferative/growth inhibition signal resulting in apoptosis. This is known to occur via the release of cytochrome c (Juin et al., 1999) and is prevented by IGF-1 which serves as a survival factor. Cyclin D1 expression leads to inactivating phosphorylation of Rb, releasing E2F-1 which is then free to participate in transactivation of the MYC promoter (Oswald et al., 1994) . Notably, cyclin D1 expression in human breast cancer cells is sucient to prevent cell cycle exit even in low serum when control cells are blocked in G1 or quiescent (Zwijsen et al., 1996) . Thus, at least in some cell types, cyclin D1 expression may resemble MYC expression, resulting in apoptosis in cells cultured without growth factor support. Indeed, rat ®broblasts expressing ectopic cyclin D1 undergo apoptosis in conditions of serum starvation (Sofer-Levi and Resnitzky, 1996) . In the present study we show that cyclin D1 expression sensitizes breast cancer cells to RA, in that this ligand which otherwise primarily causes cell cycle arrest, now induces widespread apoptosis. There is good evidence to suggest that treatment of breast cancer cells with RA itself results in a type of growth factor withdrawal in that numerous groups have shown that the expression of IGF-binding protein-3 is strongly induced by RA. This eectively attenuates the growth promoting eects of autocrine IGF-1 on breast cancer cells (Oh et al., 1995; Shang et al., 1999) . Whether the increased level of apoptosis in cyclin D1 stable clones is a direct consequence of cyclin D1 supported cdk activity or results from the activation of pro-apoptotic Bcl-2 family proteins which then renders the cell sensitive to RA is currently under study.
Since cyclin D1 overexpression is an early event in malignant progression of breast epithelial cells, our ®ndings may impact on the understanding of the mechanism by which RA acts as a chemopreventive agent. In this respect it is interesting to note that formation of N-methyl-N-nitrosourea-induced rat mammary tumors express high levels of cyclin D1 (Sgambato, 1995; Sukumar et al., 1995) and are strongly inhibited by retinoid feeding Moon et al., 1992) .
Apoptotic signals act through the members of the Bcl-2 family to induce cell death. While Bcl-2 is constitutively membrane bound, the Bax protein is predominately cytoplasmic in many cells and Bcl-x L distributed between membrane and cytoplasmic locations. Induction of apoptosis by diverse signals results in the translocation of Bax to the membrane component . The signi®cance of this conforma-tional change resulting in NH 2 -terminal exposure is that it is associated with availability and activation of the BH3 domain of Bax which is necessary for altering mitochondrial permeability resulting in cytochrome c release and ensuing apoptosis (Gross et al., 1999; Desagher et al., 1999) . Original proposals that Bax and Bcl-2 regulate apoptosis by stoichiometric homo and hetero-dimeric interactions have been complicated by the fact that mitochondrial membrane-bound Bax is not associated as homodimers or heterodimers with Bcl-2 or Bcl-x L . The observation that Bcl-2 overexpression both attenuated RA-induced cell death and prevented Bax NH 2 -terminal exposure suggests that Bcl-2 plays a fundamental role in controlling death/damage signal-mediated conformational changes in Bax. These results are in accord with Murphy et al. (2000) who also found that Bcl-2 overexpression could prevent the Bax conformational change associated with Fas-induced apoptosis. Interestingly we were able to detect low levels of activated Bax in the absence of RA particularly in the cyclin D1-expressing cells. It is possible that this conformational change in Bax eventually leads to apoptosis at a low frequency in the absence of RA. Alternatively, Bax NH 2 -terminal exposure may itself be insucient to initiate the cell death pathway in the absence of RA, perhaps because of the relatively high levels of Bcl-2 in untreated MCF-7 cells.
Ours is the ®rst study of the eect of dysregulated expression of cyclin D1 on retinoid sensitivity in breast cancer cells. Similar to breast cancer cell lines, nontransformed normal human mammary epithelial cells (HMECs) undergo an RA-mediated G0/G1 growth arrest (Seewaldt et al., 1997) . However, retroviralmediated expression of cyclin D1 in HMECs prevented the G0/G1 arrest induced by RA without producing apoptosis (Seewaldt et al., 1999) . The implication of these combined ®ndings is that transformed but not normal mammary epithelial cells express components of a signaling pathway which converts the RA growth inhibitory signal to an apoptotic signal even though both are ectopically expressing cyclin D1. This suggests that at least for mammary-derived epithelial and carcinoma cells, dysregulated expression of cyclin D1 may confer dierential sensitization to apoptotic stimuli and may provide a useful marker for kinetic drug sensitivity in breast cancer.
Materials and methods

Cell culture and transfections
MCF-7 cells and ZR-75 cells grow in DMEM (high glucose) with 5% fetal bovine serum, 1% non-essential amino acids, 110 mg/ml sodium pyruvate and 10 mg/ml gentamicin. For treatment with RA, 100 mm plates were seeded with 5610 5 cells and made 1 mM with RA in or the equivalent amount of ethanol vehicle after attachment. Cells were harvested at the indicated times. Expression plasmids for human cyclin D1 and Bcl-2 were in pcDNA3 (Invitrogen, Carlsbad, CA, USA). Cells were stably transfected for 6 ± 8 h with 15 mg of plasmid DNA for each 100 mm culture dish using the BES buer calcium phosphate method (Chen and Okayama, 1987) . After removal of the precipitate, the cells were shocked for 3 min with a solution containing 20% glycerol in DMEM with 2% fetal calf serum, grown to con¯uence, then split 1 : 10 in selective medium containing 1 mg/ml G418. Selected colonies were transferred to 24 well plates for expansion.
Plasmids and antibodies
The human cyclin D1 cDNA was obtained from Dr Paul Hamel (Toronto, Canada). Bcl-2 cDNA was obtained from Dr Stanley Korsmeyer (Harvard). Anti-cyclin D1 monoclonal (HD11) was from Santa Cruz Biotech (Santa Cruz, CA, USA); anti-Bax 6A7 monoclonal was from Trevigen (Gaithersburg, MD, USA); anti-cytochrome c monoclonal antibody was obtained from Pharmingen (Mississauga, ON, Canada); anti-cytochrome c oxidase was purchased from Molecular Probes, (Eugene, OR, USA): Bcl-2 and caspase-9 antibodies have been previously published (Krajewski et al., 1999) . Secondary antibodies conjugated to horseradish peroxidase (HRP) and CY3 were obtained from Jackson Laboratories (West Grove, PA, USA).
Mitochondrial preparation
Subcon¯uent cultures were collected by trypsinization, centrifuged in medium containing 5% serum and washed in phosphate-buered saline (PBS) (137 mM NaCl, 27 mM KCl, 10 mM Na 2 HPO 4 , KH 2 PO 4 ). The cell pellet was resuspended in 550 ml ice cold RSB (10 mM NaCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl, pH 7.5), swelled on ice for 10 min and disrupted with 20 strokes of a Dounce homogenizer. Immediately afterwards 0.4 ml of 2.56MS buer (525 mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl, pH 7.5, 2.5 mM EDTA, pH 7.5) and a protease inhibitor cocktail (phenylmethylsulphonyl¯uoride/aprotinin/pepstatin) were added prior to centrifugation twice at 1300 g to remove the nuclei, unbroken cells and large membrane fragments. The supernatant was then transferred to a microfuge tube and the mitochondria pelleted at 17 000 g for 15 min then resuspended in 50 ml of RIPA buer (1% NP-40, 0.5% deoxycholate, 0.1% SDS in PBS).
Immunoblot
Cultures were harvested into pre-chilled microfuge tubes in 500 ml RIPA buer containing a protease inhibitor cocktail. After 10 min on ice cells were homogenized using a 22 G needle then centrifuged at 15 000 g for 20 min at 48C to remove particulates. Protein lysates were stored at 7808C until use. Protein concentrations were measured using the Bio-Rad (Hercules, CA, USA) protein Assay Reagent and 20 ± 30 mg of protein was subjected to 10 or 12.5% SDS polyacrylamide gel electrophoresis. Proteins were transferred electrophoretically to PVDF membranes and blocked for 1 h in Tris-buered saline with 0.1% Tween 20 (TBS-T) and 5% skim milk. Membranes were incubated with primary antibodies diluted in TBS-T/5% skim milk at room temperature (RT) for 1 h, washed three times in TBS-T and incubated a further 30 min in horseradish peroxidase conjugated secondary antibody diluted 1 : 5000 in TBS-T/ 5% skim milk. Immunoreactive bands were visualized by development with Renaissance enhanced chemiluminescence reagent (NEN, Boston, MA, USA) and exposure to Hyper®lm (Amersham-Pharmacia, Baie d'UrfeÂ , QC, Canada).
Cell cycle analysis
Cells were collected at 48C by centrifugation at 500 g for 5 min in PBS with 1 mM EDTA. Cells were resuspended in 1 ml of ice cold PBS/EDTA then ®xed by the addition of 3 ml of 80% ice cold ethanol and stored at 7208C until analysis. For¯ow cytometric analysis an aliquot of ®xed cells were centrifuged at 500 g for 5 min, washed with PBS/EDTA then resuspended in ice cold PBS/EDTA, treated with 100 mg/ml RNase A for 20 min at RT and made 32 mM with propidium iodide. Data was acquired on a Coulter Diagnostics (Hialeah, FL, USA) model Epics Altra¯ow cytometer and cell cycle analysis was performed using the Multicycle AV program for Windows (Phoenix Flow Systems, San Diego, CA, USA).
Immunocytochemistry
Cells were cultured in 35 mm dishes on coverslips and at the appropriate times ®xed with 3% formaldehyde in PBS at RT then permeabilized for 2 min with 0.2% CHAPS in PBS. Mouse anti-Bax monoclonal 6A7 was used at a 1 : 300 dilution in 3% bovine serum albumen in PBS and incubated with coverslips for 1 h at RT. Immunostained cells were detected following a 1 h incubation at RT with CY3-labeled goat anti-mouse secondary antibody. Coverslips were mounted with anti-fade (glycerol containing 1 mg/ml pphenylene-diamine). For Hoechst staining, cells were ®xed on coverslips with cold methanol at 7208C for 5 min then incubated in a 1 : 1500 dilution in water of 0.5 mg/ml Hoechst 33258 at RT, washed with PBS then mounted on coverslips with anti-fade. Image capture and slide evaluations were performed using a Zeiss Axiophot¯uorescence microscope equipped with Northern Eclipse image analysis software (EMPIX Imaging Inc., Mississauga, ON, Canada).
BrdU labeling
Subcon¯uent cells were incubated in the presence of 10 mM BrdU (Becton-Dickinson, Mississauga, ON, Canada) then ®xed in ice cold methanol for 5 min, rinsed with PBS, denatured in 2 M HCl for 10 min at RT and neutralized with 0.1 M Na borate pH 8.5 for 10 min. After washing with ice cold 0.5% Tween 20 in PBS, monoclonal anti-BrdU antibody (Becton-Dickinson) was added at a dilution of 1 : 50 for 1 h at RT. Following three washes in PBS, coverslips were incubated with donkey anti-mouse CY3 (1 : 100), washed three times in PBS and mounted with anti-fade.
In situ end labeling (ISEL) ISEL was performed essentially as described by Fliss and Gattinger (1996) . Brie¯y, cells were ®xed onto coverslips in 1% glutaraldehyde. Free 3' hydroxyl DNA ends were labeled with biotin-16 dUTP (Boehringer Mannheim, Canada) using terminal transferase. Labeled ends were detected following binding of avidin conjugated-¯uoroscein isothiocyanate. Slides were treated with anti-fade, coverslips applied and images obtained from the¯uorescence microscope as described above.
